{"id":5872,"date":"2020-02-20T12:53:38","date_gmt":"2020-02-20T12:53:38","guid":{"rendered":"http:\/\/www.library.sath.nhs.uk\/research\/?p=5872"},"modified":"2021-03-22T09:57:02","modified_gmt":"2021-03-22T09:57:02","slug":"will-weekly-win-for-taxol-in-the-uk-comparison-of-outcomes-in-metastatic-and-locally-advanced-breast-cancer-with-weekly-vs-3-weekly-administration-of-paclitaxel-a-randomised-two-arm-prospective-mu","status":"publish","type":"post","link":"https:\/\/www.library.sath.nhs.uk\/research\/2020\/02\/20\/will-weekly-win-for-taxol-in-the-uk-comparison-of-outcomes-in-metastatic-and-locally-advanced-breast-cancer-with-weekly-vs-3-weekly-administration-of-paclitaxel-a-randomised-two-arm-prospective-mu\/","title":{"rendered":"Will Weekly Win for Taxol in the UK: Comparison of Outcomes in Metastatic and locally advanced breast cancer with weekly vs. 3 weekly administration of paclitaxel: A randomised two-arm, prospective, multi-centre, open-label phase III trial comparing the activity and safety of a weekly versus a three-weekly paclitaxel treatment schedule in patients with advanced or metastatic breast cancer (2019)"},"content":{"rendered":"

Type of publication:<\/strong>
\nRandomised controlled trial<\/p>\n

Author(s):<\/strong>
\nCameron, D. and Verrill, M.<\/p>\n

35 patients from Shrewsbury and Telford Hospital NHS Trust were involved in this trial.<\/p>\n

Citation:<\/strong>
\nUnpublished final report<\/p>\n

Abstract:<\/strong>
\nBackground: Paclitaxel has significant anti-tumour activity in patients with metastatic breast cancer who either relapse after, or are resistant, to anthracycline based treatment. In this setting, paclitaxel was routinely given as a 3-hour IV infusion at a dose of 175 mg\/m2 every 3 weeks. With the aim of optimising dose and schedule of paclitaxel for patients with metastatic breast cancer, a weekly, dose-dense regimen was developed and used in various settings.
\nPatients and Methods: A total of 569 patients were recruited into the trial \u2013 the first and last patients were randomised on 16 September 2002 and 31 July 2006 respectively. The 2 arms were well balanced for sites of metastases, extent of prior radiotherapy and chemotherapy. The median follow up at May 2012 (when the final analysis was performed) was 94 months = 7 years, 10 months.
\nResults: Response rates for the weekly regimen were significantly higher than the 3-weekly arm (chi-squared test of association: p = 0.002; responses were weekly CR 3.2%, PR 18.3% vs. 3-weekly CR 1.7% and PR 11.3%). There was no significant difference in either time to progression (log rank test: p = 0.127) or overall survival (log rank test: p = 0.193) between the 2 arms.
\nConclusions: In this randomised controlled trial of best scheduling, weekly paclitaxel showed a statistically higher objective response activity compared to 3-weekly schedule but no survival benefit was seen.<\/p>\n","protected":false},"excerpt":{"rendered":"

Type of publication: Randomised controlled trial Author(s): Cameron, D. and Verrill, M. 35 patients from Shrewsbury and Telford Hospital NHS Trust were involved in this trial. Citation: Unpublished final report Abstract: Background: Paclitaxel has significant anti-tumour activity in patients with…<\/span><\/p>\n

Read more Will Weekly Win for Taxol in the UK: Comparison of Outcomes in Metastatic and locally advanced breast cancer with weekly vs. 3 weekly administration of paclitaxel: A randomised two-arm, prospective, multi-centre, open-label phase III trial comparing the activity and safety of a weekly versus a three-weekly paclitaxel treatment schedule in patients with advanced or metastatic breast cancer (2019)<\/span> ›<\/span><\/a><\/div>\n

<\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[200],"tags":[832,245,353],"class_list":["post-5872","post","type-post","status-publish","format-standard","hentry","category-staff-publication","tag-832","tag-breast-cancer","tag-oncology"],"_links":{"self":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/5872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/comments?post=5872"}],"version-history":[{"count":2,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/5872\/revisions"}],"predecessor-version":[{"id":5874,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/5872\/revisions\/5874"}],"wp:attachment":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/media?parent=5872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/categories?post=5872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/tags?post=5872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}